 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...4445464748495051525354...235236» |
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Esa noticia, que reseña un estudio con 1128 pacientes de 200 hospitales a lo largo de ocho años (5 de seguimiento), exagera el resultado de un ensayo casi insignificante, se ilustra con un plan de los 70, y trata el FOLFOX como si fuera un tratamiento inocuo, y no lo es. (Twitter) - Jun 7, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Long term Grade 2-3 neuropathy is negligible with 3 mo of CAPOX or FOLFOX . Data from IDEA- Asia trial https://t.co/JPyixKLF0D (Twitter) - Jun 7, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
What references would you recommend for understanding the late neuropathy toxicity from Ox? It would be helpful to get an idea of what percent of the 82% in the FOLFOX arm that had neuropathy will have lasting sequalae down the road (Twitter) - Jun 7, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: doubling the length of adjuvant FOLFOX from 6x in Group 1, to 12x in Group 2, doesn't sound like "de-escalation" to me (Twitter) - Jun 7, 2023
- | Repatha (evolocumab) / Amgen, Astellas
Trial primary completion date, Metastases: Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 7, 2023
P1, N=12, Recruiting, Sponsor: CHU de Quebec-Universite Laval
Trial primary completion date: Dec 2025 --> Jan 2025
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - Jun 7, 2023
P1, N=52, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2025 --> Jan 2025 Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
- | epacadostat (INCB024360) / Incyte
Phase classification, Trial completion date, Trial primary completion date: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jun 7, 2023
P1/2, N=39, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026 Phase classification: P1 --> P1/2 | Trial completion date: Jun 2027 --> Aug 2030 | Trial primary completion date: Dec 2026 --> Jul 2027
- || leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg., pyrimethamine / Generic mfg.
Clinical, Journal: IgM triplet in neonatal diagnosis by immunoblotting and its potential use as a diagnostic marker for congenital toxoplasmosis. (Pubmed Central) - Jun 6, 2023
The presence of the triplet appears pathognomonic for the diagnosis of CT, and it increased the sensitivity of the immunoblot assay from 55.04% to 72.48%. As a result, it would be wise to enhance conventional immunoblot reading by adding the presence of the three IgM bands in the infant pattern for neonatal diagnosis of CT.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Could unbalanced genomic drivers between arms explain some of this? SMAD4 mutations associated with lack of response to NA FOLFIRINOX and early progression https://t.co/sgVUc0zlE6 (Twitter) - Jun 6, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Adherence: I don’t know the data enough on this. But if FOLFOX has been moved into the neoadjuvant setting to improve adherence, could there be more neuropathy, toxicity from receiving more cycles of chemotherapy? (Twitter) - Jun 6, 2023
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Journal, Metastases: The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. (Pubmed Central) - Jun 6, 2023
As a result, it would be wise to enhance conventional immunoblot reading by adding the presence of the three IgM bands in the infant pattern for neonatal diagnosis of CT. These real-world data confirm the 5-FU/LV-nal-IRI efficacy and safety in advPDAC patients progressed to gemcitabine-based therapy, with outcomes comparable to NAPOLI-1, even in a less-selected population and with more modern therapeutic algorithm.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
@BenWestphalen makes an excellent practical point from FOOTPATH trial: can use alternating FOLFOX/FOLFIRI with similar outcomes if concerned about toxicities with triplet. Takeaway 👍 #ASCO23 (Twitter) - Jun 6, 2023
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Trial initiation date: Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (clinicaltrials.gov) - Jun 6, 2023
P1, N=20, Not yet recruiting, Sponsor: University of California, Irvine
These real-world data confirm the 5-FU/LV-nal-IRI efficacy and safety in advPDAC patients progressed to gemcitabine-based therapy, with outcomes comparable to NAPOLI-1, even in a less-selected population and with more modern therapeutic algorithm. Initiation date: Apr 2023 --> Dec 2023
- || Ampligen (rintatolimod) / AIM ImmunoTech
Trial initiation date: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) - Jun 6, 2023
P2, N=90, Recruiting, Sponsor: AIM ImmunoTech Inc.
Initiation date: Apr 2023 --> Dec 2023 Initiation date: Mar 2023 --> Jun 2023
- ||| AB598 / Arcus Biosci
New P1 trial, Combination therapy, Monotherapy, Metastases: ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov) - Jun 6, 2023
P1, N=81, Not yet recruiting, Sponsor: Arcus Biosciences, Inc.
- ||| Enrollment open, Trial initiation date: TRIPP-FFX: FOLFIRINOX Versus OncoSil (clinicaltrials.gov) - Jun 6, 2023
P2, N=80, Recruiting, Sponsor: OncoSil Medical Limited
Initiation date: Mar 2023 --> Jun 2023 Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Apr 2023
- || Herceptin (trastuzumab) / Roche, emavusertib (CA-4948) / Curis, Dr. Reddy's
Enrollment open: CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer (clinicaltrials.gov) - Jun 6, 2023
P1, N=42, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Apr 2023 Not yet recruiting --> Recruiting
- | Journal: Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. (Pubmed Central) - Jun 5, 2023
P=N/A
In this prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma, patients did not derive clinical benefit from fluorouracil-based chemotherapy, given there were no objective responses, no difference in OS when treatment was delayed 6 months, and no difference in the rate of tumor growth while receiving chemotherapy. ClinicalTrials.gov Identifier: NCT01946854.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Surgery: The #OncoAlertTopTweet 🚨 Day 4 of #ASCO23 🌐 An honor to present our @OncoAlert 🚨 #PancreaticCancer faculty @BenWestphalen discussing: NORPACT1 Short NeoAdj FOLFIRINOX Vs Surgery Best, @weoncologists (Twitter) - Jun 5, 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal, Metastases: FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study. (Pubmed Central) - Jun 5, 2023
FOLFIRI (folinate, 5-fluorouracil and irinotecan) is a chemotherapy regimen used in digestive neuroendocrine carcinoma, which shares pathological similarities with SCLC...FOLFIRI could represent a potential new treatment for platinum-resistant/refractory SCLC patients. Further prospective studies are needed to assess the benefits of this chemotherapy regimen.HIGHLIGHTSFOLFIRI showed some activity for platinum-resistant/refractory SCLC in terms of overall response.FOLFIRI was well-tolerated in platinum resistant/refractory SLCL patients.FOLFIRI could represent a potential new treatment for SCLC, prospective studies are needed.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
FOLFOX ain't that brutal , you trying to pull a NYT? (Twitter) - Jun 5, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: However, short course RT 5 Gy x 5 fx, is also reasonable for patients in this population and is arguably more convenient and less toxic than FOLFOX. Some patients also may not need neoadjuvant treatment at all per ASTRO or ESMO guidelines as pointed out by @NiuSanford (Twitter) - Jun 5, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Metastases: Catching up on PROSPECT: A randomized ph III trial of neoadj Chemo-RT vs neoadj FOLFOX with selective use of chemo-RT, => by TME for tx of locally advanced rectal cancer, plenary talk by Dr. @debschrag #ASCO23 #rectalcancer Nice simple language summary at https://t.co/e9wmbmMibB (Twitter) - Jun 5, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Thank you for these important clarifications +++ Is chemotherapy with FOLFOX a therapeutic de-escalation in this population of patients ? A discussion based on the PROs will be important for the therapeutic choice. (Twitter) - Jun 5, 2023
- | irinotecan / Generic mfg.
Journal: Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma. (Pubmed Central) - Jun 5, 2023
Further prospective studies are needed to assess the benefits of this chemotherapy regimen.HIGHLIGHTSFOLFIRI showed some activity for platinum-resistant/refractory SCLC in terms of overall response.FOLFIRI was well-tolerated in platinum resistant/refractory SLCL patients.FOLFIRI could represent a potential new treatment for SCLC, prospective studies are needed. Pharmacokinetically-guided dose adjustment of standard chemotherapy treatments might improve survival outcomes in patients with pancreatic ductal adenocarcinoma.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. (Pubmed Central) - Jun 5, 2023
The diversity of gut microbiota was neither decreased by NAC for R/BR-PDAC nor associated with postoperative complications. Lower incidence of Bifidobacterium genus before NAC may be associated with a lower pathological response to NAC.
- || 5-fluorouracil / Generic mfg.
Review, Journal: Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. (Pubmed Central) - Jun 5, 2023
Different from hepatocellular carcinoma in China, hepatocellular carcinoma in Western countries is caused by hepatitis C and alcoholic liver disease, and is often diagnosed at an early stage, when the tumor is small or the thrombus is not serious. Although there are no reports of FOLFOX-HAIC efficacy for hepatocellular carcinoma in Western countries, FOLFOX-HAIC can be used in patients with large tumors (> 5 cm) (or T3 by TNM stage), and rich blood supply.
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Circulating tumor DNA: Case#2 #ctDNA in the Management of Early Colorectal Cancer:The Time Has Come! #ASCO23 #CRCSMGreat case! ctDNA (-) now Wwyd? Duration of adj IO? Dr.P: 1 or 2Y seems overkill, gave 6M Dr.T: repeat ctDNA. IO not 2Y, 6m-1Y maybe or 9m? If ctDNA (+), wwyd? Dr. T: no FOLFOX, Combi IO (Twitter) - Jun 5, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Surgery: Dear Colleagues at #ASCO23 An honor to present our @OncoAlert 🚨 #PancreaticCancer faculty @BenWestphalen 🇩🇪 discussing: NORPACT1 Short NeoAdj FOLFIRINOX Vs Surgery Best, @weoncologists @Aiims1742 @ArndtVogel @CathyEngMD @manjuggm @ARosen380 @stacy_hurt @GraceCordovano… https://t.co/6261sp5Efl (Twitter) - Jun 5, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Surgery: Dear Colleagues at #ASCO23 An honor to present our @OncoAlert 🚨 #PancreaticCancer faculty @BenWestphalen 🇩🇪 discussing: NORPACT1 Short NeoAdj FOLFIRINOX Vs Surgery Best, @weoncologists @Aiims1742 @ArndtVogel @CathyEngMD @manjuggm @ARosen380 @stacy_hurt @GraceCordovano… https://t.co/CDEQPJCeuZ (Twitter) - Jun 5, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Adverse events: So you prefer doubling the G3 toxicity of this subset of patients (>40%) and exposing them to late side effects of many cycles of FOLFOX (severe neuropathy, second tumors, cardiovascular deaths). But yes, you can actually spare the "brutal" effects of RT... @toddscarbrough (Twitter) - Jun 5, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Metastases: Sequela of Pelvic RT is less than that of FOLFOX ( proportion wise) per study. Are you really doing less by giving more toxicity ? ( RT also much more advanced) (Twitter) - Jun 4, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: 2/2 you can’t compare grd 4 neutropenia with FOLFOX to grd 3 diarrhea with RT although one is grd 3 and other is grd 4. Also consider all the long term RT issues for females. 25 trips for RT is often emotionally and financially draining for many rural area pts. (Twitter) - Jun 4, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Adverse events: FOLFOX contains 2 relatively cheap meds. 6 cyc of FOLFOX will involve patients 6 infusion trips with 2-3 symptom check visit. Compare that to 25 trtmt visits to get pelvic RT. I would be curious to know the details about g3/g4 side effects are. 1/2 (Twitter) - Jun 4, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: .@TGeorgeMD is a coauthor on the PROSPECT trial study that @UFHealth participated in, showing neoadjuvant FOLFOX was noninferior to chemoradiotherapy for disease-free survival for patients with #RectalCancer. #ASCO23 Read more in the @nytimes: https://t.co/hqPfcdSU13 (Twitter) - Jun 4, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Forgot to add that if you end up taking 22 weeks of FOLFOX there is a 10% chance of you getting Radiotherapy as well. (Twitter) - Jun 4, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Adverse events: This trial supports omission of neoadjuant FOLFOX in well selected rectal cancer patients. No detriment in outcomes, lower adverse effects - short and long term as well as reduced time toxicity all favouring CRT. (Twitter) - Jun 4, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Patient reported outcomes: PROSPECT Patient reported outcomes showed differential toxicities between FOLFOX + selective CRT vs. CRT. Superior sexual function reported by men and women in the FOLFOX arm. @JCO_ASCO https://t.co/N0q3Iw2qKD (Twitter) - Jun 4, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: ✨FOLFOX followed by selective chemoradiotherapy can replace standard neoadjuvant chemoradiotherapy. ✨Largest benefit is less long-term radiotherapy-related toxicity. ✨Shared decision making advised in all cases! @JCO_ASCO @OncoAlert #ASCO2023 #ASCO23 (Twitter) - Jun 4, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
P3 data: Mature outcomes of #PRODIGE23 show improved OS with FOLFIRINOX TNT. ➡️ Supports current JANUS trial to increase cCR. ➡️ May support enlarging JANUS trial to Phase III to directly compare DFS/OS of the two TNT regimens. @CathyEngMD @JoshSmithMDPhD @TGeorgeMD @adasarimd (Twitter) - Jun 4, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Head-to-Head: Non-inferiority trial. Interesting findings though. Would be keen to see a comparison of 5x5 Gy followed by FOLFOX vs. FOLFOX. (Twitter) - Jun 4, 2023
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
It also remains controversial weather a chemo regime containing Oxaliplatin is better tolerated both short and long term compared to radiotherapy. A comparison between 5x5 + FOLFOX vs. FOLFOX would be more compelling anyway (Twitter) - Jun 4, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Maybe we should question if we’re overdoing the RT dosing, volumes, and the number of cycles of FOLFOX when the two are combined in this fashion? (Twitter) - Jun 4, 2023
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Patient reported outcomes, Metastases: Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). (Pubmed Central) - Jun 4, 2023
Although there are no reports of FOLFOX-HAIC efficacy for hepatocellular carcinoma in Western countries, FOLFOX-HAIC can be used in patients with large tumors (> 5 cm) (or T3 by TNM stage), and rich blood supply. For patients with locally advanced rectal cancer choosing between neoadjuvant FOLFOX and 5FUCRT, the distinctive PRO profiles inform treatment selection and shared decision making.
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Alliance N1048 PROSPECT rectal cancer trial of neoadjuvant 5FUCRT vs FOLFOX plus selective use of 5FUCRT. Noninferior DFS. Longer-term PRO-CTCAE & other PROs tip the scale to FOLFOX! https://t.co/9FZv8ooAKw @ALLIANCE_org @debschrag @EthanBasch1 @GitaThanaMD (Twitter) - Jun 4, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: Dear Krishan, 7y OS number of FOLFIRINOX arm lies within 95% CI of SOC arm. HOWEVER, difference was claimed to be significant. I mean it is so close to insigificance. And, FOLFIRINOX is a so heavy chemo regimen not suitable for majority of pts outside a RCT What do u think? (Twitter) - Jun 4, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Surgery: Upfront surgery versus neoadjuvant FOLFIRINOX for PDAC. Results favor surgery based on presentation. (Twitter) - Jun 4, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Somebody said « Fancy FOLFIRINOX! » (Twitter) - Jun 3, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: Now live: Upper GI, hepato-biliary & pancreatic oral abstracts. Looking forward to updates from NAPOLI-3 & the long awaited NORPACT-1 trial on neoadjuvant FOLFIRINOX in #pancreaticcancer Here with me @heinrich_kat Friendly Faces #ASCO23 😀 #pancsm 💜 @OncoAlert 🚨 (Twitter) - Jun 3, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Would like to see results stratified by total dose of FOLFIRINOX and compare neo- vs adj… maybe it’s more about the dose than timing as long as resectable? @ksoreide 🤓 (Twitter) - Jun 3, 2023